Yesterday, Scandinavian Medical Solutions reported its 2023/24 results and announced its new 2024/25 guidance. The 2023/24 results were within the company's guidance, and the new guidance ranges for 2024/25 correspond to between 6-19% revenue growth and an EBITDA margin between 9-12%. After investments in 2023/24, including in the organization and infrastructure, the US subsidiary, and its Aftersales & Parts and Rental business areas, the foundation is now built for the next growth phase.  We have updated our investment case one-pager following the 2023/24 results, new 2024/25 guidance, and recent news. Besides an overview of financials and valuation multiples, the investment case one-pager introduces Scandinavian Medical Solutions and highlights key investment reasons and risks. Earlier today, Scandinavian Medical Solutions' CEO Jens Hvid Paulsen and Head of Sales Martin Lind presented the 2023/24 report and new expectations in an online live event (in Danish). Watch the presentation here: https://www.inderes.dk/videos/scandinavian-medical-solutions-praesentation-af-arsrapporten-202324 Disclaimer: HC Andersen Capital receives payment from Scandinavian Medical Solutions for a Digital IR/Corporate Visibility subscription agreement. /Kasper Lihn 15:00, 21 November 2024.

info@inderes.fi (inderes.fi)

© Inderes Oyj. All rights reserved.